Day 1 | Day 2 | Download Brochure
TUESDAY, JUNE 5
7:15 am Registration & Morning Coffee
Program Scientific Advisor: Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology Center for Neurologic Diseases Brigham and Women’s Hospital
8:00 Chairperson’s Opening Remarks
Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals
8:10 Talk Title to be Announced
Marcelle Bergeron, Ph.D., Director, Neuropharmacology, Elan Pharmaceuticals
8:40 Hunting for IgG Biomarkers for Alzheimer’s
Dwight German, Ph.D., Professor, Department of Psychiatry, University of Texas Southwestern Medical Center
Using a 15,000 peptoid library, we have identified 3 Alzheimer’s disease (AD)-related peptoids that capture markedly elevated serum IgGs compared to those found in normal controls and those with Parkinson’s disease. These peptoids also appear to be useful for the identification of the early stage of AD, i.e., mild cognitive impairment. Future studies will further validate these biomarkers, and identify the antigens that are recognized by the IgG antibodies
9:10 Sponsored Presentations (Opportunities Available)
9:40 Surgery and Anesthesia as Modifiers of Alzheimer’s Trajectory
Roderic G. Eckenhoff, M.D., Vice Chair for Research, Austin Lamont Professor of Anesthesiology & Critical Care, Perelman School of Medicine, University of Pennsylvania
Modern healthcare involves operative procedures that produce considerable stress, pain and inflammation. These procedures occur more frequent in the elderly, and are often followed by cognitive decline which is occasionally irreversible and associated with excess morbidity and mortality. Recent work has suggested that the trajectory of incipient Alzheimer pathology may be accelerated by features of the perioperative period, such as anesthetics or inflammation. I will summarize evidence from both pre-clinical and clinical studies, and point to the essential role for reliable biomarkers.
10:10 Coffee Break
10:40 Sponsored Presentations (Opportunities Available)
Novel Approaches To Drug Discovery Through Alternative Targets
11:10 Novel NMDA Receptor Antagonists for Treatment of AD
Adeboye Adejare, Ph.D., Professor, Pharmaceutical Sciences, University of the Sciences, Philadelphia College of Pharmacy
Apart from cholinesterase inhibitors, the only FDA approved drug for treatment of AD (memantine, Namenda®) is an NMDA receptor antagonist. In addition to decreasing over-excitation, several of the compounds are known to have anti-inflammatory and anti-oxidant properties. A recent development is that these compounds can modulate APP metabolism. The talk will focus on development of superior NMDA receptor antagonists acting by several mechanisms and the possibility of their use for AD treatment.
11:40 PP2A – A Novel Target for Alzheimer’s Disease Therapeutics
Steven Braithwaite, Ph.D., Senior Vice President, Drug Discovery, Neuroscience, Signum Biosciences
Phosphoprotein phosphatase 2A (PP2A) is the master regulator of tau phosphorylation state and a central regulator of cellular function. Our identification of a safe and efficacious mechanism to enhance PP2A activity indicates that it is a drugable target. We have identified compounds targeting this mechanism that display efficacy in multiple models of Alzheimer's disease - modulating critical biochemical and pathological processes and improving cognition. PP2A therefore stands as a novel and tractable disease modifying target for Alzheimer's disease.
12:10 pm Luncheon Presentation
Sponsored by
Development of Analytically Validated CSF Biomarker Assays for Alzheimer’s Disease
Pankaj Oberoi, Ph.D., Director, Scientific Services and Research & Development, Meso Scale Discovery
1:10 Session Break
1:30 Chairperson’s Remarks
Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology Center for Neurologic Diseases Brigham and Women’s Hospital
1:40 Enhancing Antibody Uptake in Brain to Target BACE1
Jasvinder K. Atwal, Ph.D., Senior Research Associate, Neuroscience, Genentech
2:10 EXPERT PANEL: The Mild Cognitive Impairment Test
Moderator: Corinne Augelli-Szafran, Ph.D., Director, Laboratory for Experimental Alzheimer Drugs (LEAD), Harvard Medical School, Department of Neurology; Center for Neurologic Diseases Brigham and Women’s Hospital
» 2:40 KEYNOTE PRESENTATION
Converting Knowledge of Ab Biology into Disease-Modifying Therapeutics
Dennis J. Selkoe, M.D., Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School; Co-Director, Center for Neurologic Diseases, Brigham and Women’s Hospital
The central quest of research on Alzheimer’s disease is to identify precisely what process first interferes with episodic declarative memory and then prevent that process. Soluble Aß oligomers isolated directly from AD cortex impair synaptic form and function and induce tau hyperphosphorylation and neuritic dystrophy. Based on this knowledge, attempts to develop effective A-lowering agents have brought us to human trials that have provided preliminary evidence of apparent cognitive and biomarker benefit.
|
3:40 Refreshment Break in the Exhibit Hall with Poster Viewing
4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.
5:40 Welcome Reception in the Exhibit Hall with Poster Viewing
6:45 End of Day
Day 1 | Day 2 | Download Brochure